Bionano Genomics Inc (NASDAQ: BNGO) kicked off on Monday, up 1.37% from the previous trading day, before settling in for the closing price of $0.31. Over the past 52 weeks, BNGO has traded in a range of $0.28-$2.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 32.87% over the past five years. While this was happening, its average annual earnings per share was recorded 83.44%. With a float of $85.45 million, this company’s outstanding shares have now reached $86.00 million.
Let’s look at the performance matrix of the company that is accounted for 344 employees. In terms of profitability, gross margin is 28.97%, operating margin of -493.88%, and the pretax margin is -557.95%.
Bionano Genomics Inc (BNGO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Bionano Genomics Inc is 0.64%, while institutional ownership is 11.59%.
Bionano Genomics Inc (BNGO) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -3.22 earnings per share (EPS), lower than consensus estimate (set at -0.97) by -2.25. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.44% per share during the next fiscal year.
Bionano Genomics Inc (NASDAQ: BNGO) Trading Performance Indicators
Take a look at Bionano Genomics Inc’s (BNGO) current performance indicators. Last quarter, stock had a quick ratio of 1.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.01, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.48 in one year’s time.
Technical Analysis of Bionano Genomics Inc (BNGO)
Bionano Genomics Inc (NASDAQ: BNGO) saw its 5-day average volume 3.1 million, a positive change from its year-to-date volume of 1.65 million. As of the previous 9 days, the stock’s Stochastic %D was 30.39%. Additionally, its Average True Range was 0.03.
During the past 100 days, Bionano Genomics Inc’s (BNGO) raw stochastic average was set at 4.58%, which indicates a significant decrease from 19.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.88% in the past 14 days, which was lower than the 86.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4228, while its 200-day Moving Average is $0.8020. Nevertheless, the first resistance level for the watch stands at $0.3223 in the near term. At $0.3347, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3483. If the price goes on to break the first support level at $0.2963, it is likely to go to the next support level at $0.2827. The third support level lies at $0.2703 if the price breaches the second support level.
Bionano Genomics Inc (NASDAQ: BNGO) Key Stats
The company with the Market Capitalisation of 26.66 million has total of 66,857K Shares Outstanding. Its annual sales at the moment are 36,120 K in contrast with the sum of -232,490 K annual income. Company’s last quarter sales were recorded 7,770 K and last quarter income was -16,220 K.
